The effect of the apprise mandate on use of erythropoiesis-stimulating agents and transfusion rates in patients with ovarian cancer receiving chemotherapy

Boone JD, Fauci JM, Walters CL, Whitworth JM, Bevis KS, Alvarez RD

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23266649

DOI
10.1097/IGC.0b013e318276d9da

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Aged; Aged, 80 and over; Antineoplastic Agents /therapeutic use; Blood Transfusion /adverse effects /legislation & jurisprudence /methods /statistics & numerical data; Female; Guideline Adherence /statistics & numerical data; Hematinics /administration & dosage /adverse effects /therapeutic use; Humans; Mandatory Programs /legislation & jurisprudence; Middle Aged; Neoplasms, Glandular and Epithelial /drug therapy /epidemiology /therapy; Ovarian Neoplasms /drug therapy /epidemiology /therapy; Patient Safety /legislation & jurisprudence; Retrospective Studies; United States; United States Food and Drug Administration /legislation & jurisprudence

AccessionNumber
22013018901

Date bibliographic record published
20/06/2013